Humacyte (HUMA) Other Non-Current Liabilities (2020 - 2026)
Humacyte (HUMA) posted quarterly Other Non-Current Liabilities of $1.7 million for Q1 2026, up 76.34% year-over-year from $951000.0 in Q1 2025, and up 5.94% quarter-over-quarter from $1.6 million in Q4 2025.
Humacyte (HUMA) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Other Non-Current Liabilities for 7 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 76.34% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 76.34% YoY), while the FY2025 annual figure was $1.6 million, down 34.45% from the prior year.
- Other Non-Current Liabilities advanced to $1.7 million in Q1 2026 per HUMA's latest filing, from $1.6 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $76.6 million in Q3 2024 and bottomed at $423000.0 in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $13.4 million across 5 years, with a median of $1.7 million in 2026.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities slumped 99.31% — and 2023, when it soared 9848.94%.
- Humacyte's Other Non-Current Liabilities stood at $712000.0 in 2022, then jumped by 270.22% to $2.6 million in 2023, then dropped by 8.38% to $2.4 million in 2024, then sank by 34.45% to $1.6 million in 2025, then grew by 5.94% to $1.7 million in 2026.
- Business Quant data shows HUMA's Other Non-Current Liabilities at $1.7 million in Q1 2026, $1.6 million in Q4 2025, and $3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.00 Bn | 132.14 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.24 Bn | 60.06 Bn | 1.37 Bn |
| 4 | Moderna | 62.41 Bn | 57.27 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.18 Bn | 27.88 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.93 Bn | 10.54 Bn | 668.28 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - |
| 10 | Humacyte | 154.47 Mn | 154.47 Mn | -825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.65 Mn |
| Mar 31, 2026 | 1.68 Mn |
| Dec 31, 2025 | 1.58 Mn |
| Sep 30, 2025 | 3.23 Mn |
| Jun 30, 2025 | 984,000.00 |
| Mar 31, 2025 | 951,000.00 |
| Dec 31, 2024 | 2.42 Mn |
| Sep 30, 2024 | 76.57 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Mar 31, 2024 | 830,000.00 |
| Dec 31, 2023 | 2.64 Mn |
| Sep 30, 2023 | 2.54 Mn |
| Jun 30, 2023 | 890,000.00 |
| Mar 31, 2023 | 42.08 Mn |
| Dec 31, 2022 | 712,000.00 |
| Sep 30, 2022 | 45.01 Mn |
| Jun 30, 2022 | 44.05 Mn |
| Mar 31, 2022 | 423,000.00 |
| Dec 31, 2021 | 103.66 Mn |
| Sep 30, 2021 | 555,000.00 |